Cytokine-modulating activity of tepoxalin, a new potential antirheumatic

International Journal of Immunopharmacology

Volumn 17, Issue 10, 1995, Pages 805-812

  Ritchie, David M ^a   Argentieri, Dennis C ^a   Aparicio, Beatriz L ^a   Plante, Richard K ^b   Lau, Catherine Y ^b   Barbone, Arminda G ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

^b NONE   (Canada)

Author keywords

cytokine inhibition; iron; NF B; tepoxalin

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CYTOKINE; FERRIC CHLORIDE; FERROUS CHLORIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; IRON SALT; LEFLUNOMIDE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; NABUMETONE; NAPROXEN; NEW DRUG; NUCLEAR FACTOR; OKT 3; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN SYNTHASE INHIBITOR; TENIDAP; TEPOXALIN; TUMOR NECROSIS FACTOR ALPHA; ZILEUTON; ZINC CHLORIDE;

ARTICLE; BLOOD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CELL DIVISION; CELLS, CULTURED; CYTOKINES; FERROUS COMPOUNDS; HUMAN; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LEUKOTRIENE B4; NF-KAPPA B; PYRAZOLES;

EID: 0028829414     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/0192-0561(95)00072-A     Document Type: Article

References (21)

1. New perspectives on immunointervention in autoimmune disease
2. Tepoxalin (RWJ 20485) inhibits prostaglandin and leukotriene production in adjuvant arthritic rats and in dog knee joints challenged with sodium urate and immune complexes
3. Tepoxalin (RWJ 20485 ) is a dual cyclooxygenase/5-lipoxygenase inhibitor with potent antiinflammatory activity and a favorable gastrointestinal profile
4. IL-2-induced signal transduction involves the activation of NFκB expression
5. The physiology of the NFκB transcription factor
6. Transcription factors in lymphoid development
7. Leflunomide (HWA 486): a novel immunorestoring drug
8. Recent reports of investigational drugs for leukotriene intervention
9. i and the events dependent on protein kinase C activation
10. The inducible transcription factor NFκB: structure-function relationship of its protein subunits
11. Rheumatoid arthritis, pathophysiology and implications for therapy
12. Suppression of NFκB activation and NFκB-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase
13. Inhibition of NFκB by sodium salicylate and aspirin
14. Impaired protein kinase C activation as one of the possible mechanisms of reduced lymphocyte proliferation in iron deficiency in mice
15. Inhibition of interleukin-1 synthesis by tenidap: a new drug for arthritis
16. Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with interleukin-1 synthesis inhibitors
17. New immunological treatments for rheumatoid arthritis
18. Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells (a review)
19. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen—A possible correlate with clinical acute phase response
20. Skin inflammation: reactive oxygen species and the role of iron
21. Tepoxalin: a novel immunosuppressive agent with a different mechanism of action from cyclosporine A